Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2011-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-010-1379-9PMID 20563810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study.

  2016cited by this paper
• A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

  2011cited by this paper
• Faculty Opinions recommendation of Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Targeted therapies in lung cancer.

  2009cited by this paper
• Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan.

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

  2009cited by this paper
• Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit its interaction with the EGFR in renal and epidermal cells

  2009cited by this paper
• Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents

  2008cited by this paper
• Palliative thoracic radiotherapy for lung cancer: a systematic review.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study

  2008cited by this paper
• An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

  2008cited by this paper
• Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

  2008cited by this paper
• Bivalent binding properties of epidermal growth factor receptor targeted monoclonal antibodies: Factors contributing to differences in observed clinical profiles.

  2008cited by this paper
• Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

  2007cited by this paper
• Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents

  2007cited by this paper
• Stimulated PI3K-AKT Signaling Mediated through Ligand or Radiation-Induced EGFR Depends Indirectly, but not Directly, on Constitutive K-Ras Activity

  2007cited by this paper
• K-ras mutations in non-small-cell lung carcinoma: a review.

  2006cited by this paper
• Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

  2006cited by this paper
• Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair

  2006cited by this paper
• Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin

  2005cited by this paper
• Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

  2004cited by this paper
• Signaling through the epidermal growth factor receptor during the development of malignancy.

  2004cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer

  2003cited by this paper
• Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).

  2002cited by this paper
• Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody

  2002cited by this paper
• Long-term survival in patients with non-small cell lung cancer treated with palliative radiotherapy.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

  1996cited by this paper
• Comments on A case of radiation myelopathy after 2 x 8.5 Gy for inoperable non-small cell lung cancer, Dardoufas et al., European Journal of Cancer, 31A, Nos 13/14, pp.2418-2419, 1995.

  1996cited by this paper
• Comments on A case of radiation myelopathy after 2 x 8.5 Gy for inoperable non-small cell lung cancer, Dardoufas et al., European Journal of Cancer, 31A, Nos 13/14, pp. 2418-2419, 1995.

  1996cited by this paper
• The role of palliative thoracic radiotherapy in non-small cell lung cancer.

  1996cited by this paper
• Letters to the editor: Comments on a case of radiation myelopathy after 2 × 8.5 Gy for inoperable non-small cell lung cancer, Dardoufas et al., European Journal of Cancer, 31A, Nos 13/14, pp. 2418–2419, 1995

  1996cited by this paper
• Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party.

  1996cited by this paper
• A case of radiation myelopathy after 2 x 8.5 Gy for inoperable non-small cell lung cancer.

  1995cited by this paper
• A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.

  1992cited by this paper

• Efficacy, safety, and survival outcomes of radiotherapy combined with nimotuzumab following induction chemotherapy in locally advanced head and neck cancer.

  2026cites this paper
• An Investigation of the Effect of Nimotuzumab Combined with Radiation Therapy on Gliomas

  2025cites this paper
• Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review

  2023cites this paper
• Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

  2021cites this paper
• Supplemental Online Content

  2021cites this paper
• A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

  2021cites this paper
• Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

  2020cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2020cites this paper
• Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease

  2019cites this paper
• EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

  2019cites this paper
• Necitumumab for the treatment of advanced non-small-cell lung cancer.

  2019cites this paper
• Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective.

  2019cites this paper
• Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3

  2018influential citation
• Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.

  2018cites this paper
• Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies

  2016cites this paper
• A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

  2016cites this paper
• A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

  2016cites this paper
• Brain metastases from non-small cell lung cancer : radiation therapy in the era of targeted therapies

  2016cites this paper
• Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.

  2016cites this paper
• Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors

  2016cites this paper
• Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells

  2015cites this paper
• A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer.

  2015cites this paper
• A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

  2015cites this paper
• Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair

  2015cites this paper
• Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

  2015cites this paper
• Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer

  2015cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2015cites this paper
• Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells.

  2015cites this paper
• Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer

  2015cites this paper
• Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer.

  2014cites this paper
• Nimotuzumab: A Humanized Anti‐EGFR Antibody

  2014cites this paper
• Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC.

  2014cites this paper
• The unexpected side effects and safety of therapeutic monoclonal antibodies.

  2014cites this paper
• Impacts and Interrelationships Between Medications, Nutrition, Dietary Supplements, and Oral Health

  2014cites this paper
• Trial Watch

  2014cites this paper
• The inhibitory effect of a new scFv/tP protein as siRNA delivery system to target hWAPL in cervical carcinoma

  2014cites this paper
• Comparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants.

  2013cites this paper
• Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?

  2013cites this paper
• EGFR inhibition in non-small cell lung cancer: current evidence and future directions

  2013cites this paper
• Monoclonal antibodies in lung cancer

  2013cites this paper
• Tamoxifen-induced endometrial carcinoma after a lag of 14 years

  2013influential citation
• Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience.

  2013cites this paper
• Molecularly targeted therapies in locally advanced non-small-cell lung cancer.

  2013cites this paper
• Cost-utility analysis of using nimotuzumab in end-stage cancerous patient: Is it too expensive?

  2013cites this paper
• Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin.

  2013cites this paper
• Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer

  2013cites this paper
• Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities

  2013cites this paper
• Trial watch

  2013cites this paper
• Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities

  2013cites this paper
• Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities

  2013cites this paper
• Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities

  2013cites this paper
• Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.

  2012cites this paper
• Monoclonal antibodies for the treatment of cancer.

  2012cites this paper
• A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).

  2012cites this paper
• Nimotuzumab combined with gemcitabine and cisplatin as second‐line chemotherapy for advanced non‐small‐cell lung cancer

  2012cites this paper
• PRESENTACIÓN DE CASO

  2012cites this paper
• Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

  2012cites this paper
• Nimotuzumab increases chemosensitivity of human lung adenocarcinoma cell lines to docetaxel.

  2012cites this paper
• Current world literature.

  2012cites this paper
• Trial Watch: Monoclonal antibodies in cancer therapy

  2012cites this paper
• Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer

  2012cites this paper
• Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its F(ab')2 Fragment in an Immunocompetent Mouse Model

  2012cites this paper
• Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer

  2011cites this paper
• Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

  2011cites this paper
• Radiotherapy and "new" drugs-new side effects?

  2011cites this paper
• Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer.

  2011cites this paper
• EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects

  2011cites this paper
• The emerging role of nimotuzumab in the treatment of non-small cell lung cancer

  2010cites this paper
• Oncotargets and Therapy Dovepress Dovepress Nimotuzumab plus Chemotherapy versus Chemotherapy Alone in Advanced Non-small- Cell Lung Cancer: a Multicenter, Randomized, Open-label Phase Ii Study

  year unknowncites this paper